Compare XRX & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XRX | NTHI |
|---|---|---|
| Founded | 1906 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.6M | 243.9M |
| IPO Year | 2019 | N/A |
| Metric | XRX | NTHI |
|---|---|---|
| Price | $1.76 | $9.49 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 3.4M | 31.7K |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | ★ 5.88% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $117,000,000.00 | N/A |
| Revenue This Year | $8.96 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.64 | $3.20 |
| 52 Week High | $6.80 | $16.00 |
| Indicator | XRX | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 41.59 | 48.15 |
| Support Level | N/A | $8.43 |
| Resistance Level | $2.85 | $10.52 |
| Average True Range (ATR) | 0.11 | 0.67 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 40.35 | 37.18 |
Xerox Holdings Corp is an original equipment manufacturing and software company. Xerox operates in one segment--design, development, and sale of printing technology and related solutions--while deriving 60% of its revenue from the U.S. and 40% from international markets. The company is an OEM of multifunction printers, or MFPs (printers that can print, copy, and scan), focusing on large enterprise markets. Apart from equipment, the company provides post-sales services like managed print services help to bring smart servicing and efficiencies to how employers use their print/copy equipment. Xerox is attempting to enter new markets like digital print packaging solutions and printed electronics.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).